Real-world data to support clinical evidence generation in oncology: considerations for biomarker-based cohort selection, end point assessment and other methodological issues

Randomized clinical trials remain the evidentiary gold standard for oncology, but they are often insufficient to fully characterize benefit-risk in rare cancers, biomarker-defined subgroups, and other settings where trial evidence is limited. As precision oncology advances, real-world data and real-world evidence (RWE) offer an increasingly important opportunity to address evidentiary gaps outside traditional trial populations. Yet the use of RWE in oncology requires more than access to data; it requires fit-for-purpose methods that account for the distinctive challenges of biomarker-based cohort selection, end point definition and bias mitigation. This paper reviews methodological considerations for oncology RWE generation and synthesizes selected use cases to illustrate their application in practice. We highlight unique issues arising in oncology RWE research, including incomplete or delayed biomarker ascertainment, heterogeneity in testing platforms and thresholds, misclassification of molecularly defined cohorts, variability in line-of-therapy assignment and time-related biases that can compromise interpretability. We also examine real-world end point ascertainment and discuss considerations for assessing end point validity, completeness and translatability. In addition, we outline how common oncology clinical trial end points can be operationalized as approximate real-world constructs, recognizing that differences in assessment schedule, measurement method and available data may affect comparability and performance. By integrating these methodological challenges with practical design considerations, this paper provides timely guidance to support generation of credible RWE for clinical development in oncology.

Authors

Institutions

Publication Details

Journal
Journal of Comparative Effectiveness Research
Published
2026-11-13
DOI
https://doi.org/10.57264/cer-2026-0157
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world data to support clinical evidence generation in oncology: considerations for biomarker-based cohort selection, end point assessment and other methodological issues

Mehmet Burcu, Le Su, Wei Zhou, Geoffrey Liu et al.
7 links
Journal of Comparative Effectiveness Research
Statistical Methods in Clinical Trials
article

Real-world data to support clinical evidence generation in oncology: considerations for biomarker-based cohort selection, end point assessment and other methodological issues

Mehmet Burcu, Le Su, Wei Zhou, Geoffrey Liu, Andrew N. Freedman
article en

Abstract

Randomized clinical trials remain the evidentiary gold standard for oncology, but they are often insufficient to fully characterize benefit-risk in rare cancers, biomarker-defined subgroups, and other settings where trial evidence is limited. As precision oncology advances, real-world data and real-world evidence (RWE) offer an increasingly important opportunity to address evidentiary gaps outside traditional trial populations. Yet the use of RWE in oncology requires more than access to data; it requires fit-for-purpose methods that account for the distinctive challenges of biomarker-based cohort selection, end point definition and bias mitigation. This paper reviews methodological considerations for oncology RWE generation and synthesizes selected use cases to illustrate their application in practice. We highlight unique issues arising in oncology RWE research, including incomplete or delayed biomarker ascertainment, heterogeneity in testing platforms and thresholds, misclassification of molecularly defined cohorts, variability in line-of-therapy assignment and time-related biases that can compromise interpretability. We also examine real-world end point ascertainment and discuss considerations for assessing end point validity, completeness and translatability. In addition, we outline how common oncology clinical trial end points can be operationalized as approximate real-world constructs, recognizing that differences in assessment schedule, measurement method and available data may affect comparability and performance. By integrating these methodological challenges with practical design considerations, this paper provides timely guidance to support generation of credible RWE for clinical development in oncology.

Journal of Comparative Effectiveness Research
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), National Institutes of Health (US), University of Toronto (CA), Princess Margaret Cancer Centre (CA), Ferring Pharmaceuticals (United States) (US), National Cancer Institute (US)
Good health and well-being
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon